Equities researchers at William Blair started coverage on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a report issued on Thursday, The Fly reports. The brokerage set a “market perform” rating on the stock.
A number of other research firms have also recently issued reports on IPSC. SVB Leerink reissued a “buy” rating and issued a $32.00 target price on shares of Century Therapeutics in a research note on Friday, March 18th. Zacks Investment Research raised Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $36.00.
NASDAQ:IPSC traded up $0.02 on Thursday, reaching $8.10. The company’s stock had a trading volume of 211 shares, compared to its average volume of 110,036. Century Therapeutics has a 1-year low of $7.32 and a 1-year high of $32.90. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $12.10 and its two-hundred day moving average price is $14.49.
A number of large investors have recently modified their holdings of IPSC. Citigroup Inc. acquired a new stake in Century Therapeutics during the third quarter worth approximately $34,000. Royal Bank of Canada acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $35,000. New York State Common Retirement Fund acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $53,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $94,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics in the 3rd quarter valued at $134,000. 57.50% of the stock is currently owned by institutional investors and hedge funds.
About Century Therapeutics (Get Rating)
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.